LLY Q1 2026: $19.8B Revenue, 60% Market Share, the Oral GLP-1 Era Begins

The Numbers at a Glance

• Revenue: $19.8B (+56% YoY) — crushed estimates
• Non-GAAP EPS: $8.55 (beat by $1.29)
• GAAP EPS: $8.26 (+170% YoY)
• Gross margin: 82.6% (down 0.9pp — lower realized prices, not volume)
• U.S. revenue: $12.1B (+43%)
• International revenue: $7.7B (+81%) — volume up 95%
• Stock reaction: +10.04% on earnings day (April 30)

The Two Engines: Mounjaro and Zepbound

This is not a diversified pharma story. Lilly has two drugs running a two-front war — and both are winning.

Mounjaro (tirzepatide — Type 2 Diabetes)

• Worldwide revenue: $8.66B (+125% YoY)
• Analyst estimate: $7.26B — beat by $1.4B, or ~19%
• International volume surge: 95% vs. prior year

This isn't a one-market phenomenon. Mounjaro is scaling globally at a pace that outpaced even the bulls. At $8.66B in a single quarter, it's annualizing above $34B on this drug alone.

Zepbound (tirzepatide — Obesity)

• U.S. revenue: $4.16B (+80% YoY)
• Volume up sharply; realized price declined (competition, rebates)
• Self-pay vials and telehealth channels expanding access

Zepbound's pricing headwinds are noise. The volume is what matters. 80% revenue growth on top of a declining price per unit means unit volumes grew faster — that's the durable metric.

Market Share: Lilly Is the GLP-1 Market

U.S. obesity and diabetes GLP-1 market share as of Q1 2026:

• Eli Lilly: 60.1%
• Novo Nordisk: 39.4%

One year ago this was a competitive duopoly. Today Lilly is not competing for the market — it is the market. Novo's Ozempic/Wegovy remains a serious business, but the share curve has been moving in one direction for 18 months.

Foundayo (Orforglipron) — The Category Shift

This quarter marked the first with Foundayo on market. Orforglipron is the first oral GLP-1 agonist approved for obesity — no injection, no refrigeration, no weekly pen. That is a structural expansion of the addressable patient pool.

• ~20,000+ patients treated in first weeks post-launch
• Broad pharmacy and telehealth availability from day one
• Phase 3 data also positive in Type 2 diabetes with cardiovascular risk

The injection barrier is real. Millions of patients who qualify for GLP-1 therapy have avoided it because of needles. Foundayo removes that friction. If oral dosing converts even 10-15% of treatment-hesitant patients, the total market expands materially — and Lilly is first mover with the only approved oral option.

Pipeline Beyond the GLP-1 Duopoly

• Retatrutide: Phase 3 positive in Type 2 diabetes — triple agonist (GIP/GLP-1/glucagon), potentially stronger weight loss than tirzepatide
• Jaypirca: Phase 3 positive in CLL/SLL (combo with venetoclax + rituximab)
• Taltz + Zepbound: Phase 3 positive for combo use in psoriasis with obesity — cross-selling the existing patient base

Retatrutide is the one to watch. If Phase 3 readouts confirm superior weight loss vs. tirzepatide, Lilly will have a next-generation product ready before any competitor has scaled their first-gen oral. The pipeline isn't an afterthought — it's a second wave.

Guidance: Raised Again

• Revenue: $82B–$85B (raised from $80B–$83B)
• Non-GAAP EPS: $35.50–$37.00 per share

At the midpoint of $83.5B, that's roughly 45% YoY revenue growth for the full year. The raise follows a pattern: Lilly guides conservatively, beats by a wide margin, raises. This is the third consecutive upward revision in guidance.

Trade Setup

Setup: LLY ran +10% on earnings. Prior to the print it was trading ~23% below its highs — a combination of tariff fear, PBM reform risk, and broad healthcare multiple compression. The earnings cleared the execution risk. The oral GLP-1 launch adds a new leg to the growth curve.

Risk: Realized price erosion on Zepbound (self-pay, telehealth rebates, PBM dynamics) is the structural headwind. If average selling price continues declining faster than volume grows, gross margin will follow. Also: Amgen's MariTide (monthly injection) and competitive oral entrants from Novo and others are 12–18 months away from full approval — that's when the market dynamics get more interesting.

Size: Post-gap is not the entry. Let the +10% day settle. The core thesis for LEAP positioning was a beat-and-raise at reasonable multiples — that played out. New entries should wait for a retest of the pre-earnings range or a clear consolidation base to form.

Invalidation: Mounjaro volume growth decelerates below 80% YoY, or Foundayo launch metrics disappoint in Q2 guidance commentary.

Target: A full recovery to prior highs implies 25%+ upside from pre-earnings levels. With the pipeline in play and guidance raised again, the long-term bull case is intact — but patience on entry beats chasing the gap.

Bottom Line

Lilly delivered a quarter that removed every serious doubt about execution. Revenue +56%, Mounjaro nearly doubling the analyst estimate, Zepbound volume pushing through price headwinds, and a new product category — oral GLP-1 — launched without a competitor in sight. The bear case now requires Foundayo to fail, Retatrutide to miss, and pricing to collapse simultaneously. That's a crowded thesis.

The quality is not in question. The only question is price. Let the dust settle before adding.